Stem definition | Drug id | CAS RN |
---|---|---|
antiprotozoals and radiosensitizers, metronidazole derivatives | 2671 | 19387-91-8 |
Dose | Unit | Route |
---|---|---|
0.20 | g | V |
1.50 | g | P |
2 | g | O |
2 | g | R |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 20 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 22.50 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 134.67 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 98 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 0.59 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 0.60 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.80 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 13 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
May 17, 2004 | FDA | MISSION PHARMA |
None
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug effective for unapproved indication | 58.75 | 54.36 | 10 | 134 | 2592 | 34954195 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug effective for unapproved indication | 52.46 | 42.46 | 10 | 253 | 5991 | 79738134 |
None
Source | Code | Description |
---|---|---|
ATC | A02BD09 | ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) Combinations for eradication of Helicobacter pylori |
ATC | G01AF21 | GENITO URINARY SYSTEM AND SEX HORMONES GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS Imidazole derivatives |
ATC | J01RA11 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE COMBINATIONS OF ANTIBACTERIALS Combinations of antibacterials |
ATC | J01RA13 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE COMBINATIONS OF ANTIBACTERIALS Combinations of antibacterials |
ATC | J01XD02 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER ANTIBACTERIALS Imidazole derivatives |
ATC | P01AB02 | ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS ANTIPROTOZOALS AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES Nitroimidazole derivatives |
FDA CS | M0014907 | Nitroimidazoles |
FDA EPC | N0000175435 | Nitroimidazole Antimicrobial |
MeSH PA | D000477 | Alkylating Agents |
MeSH PA | D000900 | Anti-Bacterial Agents |
MeSH PA | D000890 | Anti-Infective Agents |
MeSH PA | D000977 | Antiparasitic Agents |
MeSH PA | D000981 | Antiprotozoal Agents |
MeSH PA | D000994 | Antitrichomonal Agents |
MeSH PA | D009676 | Noxae |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Acute amebiasis | indication | 39224005 | |
Infection by Trichomonas | indication | 56335008 | DOID:1947 |
Giardiasis | indication | 58265007 | DOID:10718 |
Amebic liver abscess | indication | 75119003 | |
Bacterial vaginosis | indication | 419760006 | DOID:3385 |
Epilepsy | contraindication | 84757009 | DOID:1826 |
Peripheral nerve disease | contraindication | 302226006 | |
Neutropenic disorder | contraindication | 303011007 | DOID:1227 |
Breastfeeding (mother) | contraindication | 413712001 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 1.96 | Basic |
None
None
None
ID | Source |
---|---|
D01426 | KEGG_DRUG |
4021467 | VANDF |
C0040263 | UMLSCUI |
CHEMBL1220 | ChEMBL_ID |
DB00911 | DRUGBANK_ID |
D014011 | MESH_DESCRIPTOR_UI |
5479 | PUBCHEM_CID |
12341 | IUPHAR_LIGAND_ID |
2653 | INN_ID |
033KF7V46H | UNII |
10612 | RXNORM |
17775 | MMSL |
54062 | MMSL |
72539 | MMSL |
d04935 | MMSL |
004057 | NDDF |
324550004 | SNOMEDCT_US |
395907001 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Tinidazole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-0347 | TABLET, FILM COATED | 250 mg | ORAL | ANDA | 28 sections |
Tinidazole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-0348 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 28 sections |
Tindamax | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0178-8250 | TABLET, FILM COATED | 250 mg | ORAL | NDA | 29 sections |
Tindamax | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0178-8500 | TABLET, FILM COATED | 500 mg | ORAL | NDA | 29 sections |
Tindazole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16571-214 | TABLET, FILM COATED | 250 mg | ORAL | ANDA | 28 sections |
Tindazole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16571-215 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 28 sections |
Tinidazole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 40032-550 | TABLET | 250 mg | ORAL | ANDA | 28 sections |
Tinidazole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 40032-551 | TABLET | 500 mg | ORAL | ANDA | 28 sections |
Tinidazole | Human Prescription Drug Label | 1 | 42799-207 | TABLET | 250 mg | ORAL | ANDA | 29 sections |
Tinidazole | Human Prescription Drug Label | 1 | 42799-207 | TABLET | 250 mg | ORAL | ANDA | 29 sections |
Tinidazole | Human Prescription Drug Label | 1 | 42799-208 | TABLET | 500 mg | ORAL | ANDA | 29 sections |
Tinidazole | Human Prescription Drug Label | 1 | 42799-208 | TABLET | 500 mg | ORAL | ANDA | 29 sections |
Tinidazole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43386-550 | TABLET | 250 mg | ORAL | ANDA | 31 sections |
Tinidazole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43386-550 | TABLET | 250 mg | ORAL | ANDA | 31 sections |
Tinidazole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43386-551 | TABLET | 500 mg | ORAL | ANDA | 31 sections |
Tinidazole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43386-551 | TABLET | 500 mg | ORAL | ANDA | 31 sections |
Tinidazole | Human Prescription Drug Label | 1 | 53002-1611 | TABLET | 500 mg | ORAL | ANDA | 29 sections |
Tindamax | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-6155 | TABLET, FILM COATED | 500 mg | ORAL | NDA | 28 sections |
Tinidazole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-8386 | TABLET | 500 mg | ORAL | ANDA | 27 sections |
Tindazole | Human Prescription Drug Label | 1 | 64980-426 | TABLET, FILM COATED | 250 mg | ORAL | ANDA | 28 sections |
Tindazole | Human Prescription Drug Label | 1 | 64980-426 | TABLET, FILM COATED | 250 mg | ORAL | ANDA | 28 sections |
Tindazole | Human Prescription Drug Label | 1 | 64980-426 | TABLET, FILM COATED | 250 mg | ORAL | ANDA | 28 sections |
Tindazole | Human Prescription Drug Label | 1 | 64980-427 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 28 sections |
Tindazole | Human Prescription Drug Label | 1 | 64980-427 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 28 sections |
Tindazole | Human Prescription Drug Label | 1 | 64980-427 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 28 sections |
Tinidazole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67296-1729 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 28 sections |
Tindazole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67296-1836 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 28 sections |